Form 4: Acrivon Therapeutics Chief Legal Officer Reports Tax Withholding Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On May 14, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., filed a Form 4.
- The filing reports a transaction where 184 shares of common stock were disposed of to satisfy tax withholding requirements.
- The shares were withheld by the issuer at a price of $1.14 per share.
- Following the transaction, Miller directly owns 36,323 shares of Acrivon Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document reports a routine transaction related to tax withholding, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of stock transaction (tax withholding) |
| 05/16/2025 | Date of signature for the report |
Keywords
Form 4, Acrivon Therapeutics, Mary Miller, Chief Legal Officer, Stock Transaction, Tax Withholding, Beneficial Ownership, ACRV
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.